CXCL13 and in situ carcinoma: The CSF CXCL13 and the levels of the CXCL13 ratio decreased significantly in the CIS/RRMS‐treated group from 15.50 to 8.156 ng/L (P = 0.022) and 0.188 to 0.066 (P = 0.022), respectively.